tetramethylpyrazine has been researched along with Pulmonary Arterial Hypertension in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gu, S; Li, Y; Liu, B; Meng, Q; Qi, X; Qi, Y; Wang, X; Wen, J; Wu, M; Yu, X; Zhang, C; Zhu, W | 1 |
| Huang, H; Kong, L; Luan, S; Qi, C; Wu, F | 1 |
2 other study(ies) available for tetramethylpyrazine and Pulmonary Arterial Hypertension
| Article | Year |
|---|---|
Ligustrazine alleviates pulmonary arterial hypertension in rats by promoting the formation of myocardin transcription complex in the nucleus of pulmonary artery smooth muscle cells.
Topics: Animals; Myocytes, Smooth Muscle; Pulmonary Arterial Hypertension; Pulmonary Artery; Rats; Rats, Sprague-Dawley | 2023 |
Ligustrazine Suppresses Platelet-Derived Growth Factor-BB-Induced Pulmonary Artery Smooth Muscle Cell Proliferation and Inflammation by Regulating the PI3K/AKT Signaling Pathway.
Topics: Animals; Becaplermin; Cell Cycle; Cell Proliferation; China; Disease Models, Animal; Inflammation; Male; Myocytes, Smooth Muscle; Phosphatidylinositol 3-Kinases; Plant Extracts; Proto-Oncogene Proteins c-akt; Pulmonary Arterial Hypertension; Pyrazines; Rats; Rats, Sprague-Dawley | 2021 |